These days when we think of the words “scientific” and “sin”, we might conjure up an image of a stem cell scientist being called a sinner by extremist anti-stem cell activists. As you know, I think that is bogus. In this article that’s not the kind of scientific sin I’m talking about. Rather, I’m talking […]
Seven sins of scientists: starting with failure to cite Read More »
There is a bill being considered here in the U.S. called the “Research Works Act”. This is without a doubt one of the dumbest bills I have ever heard of in my life. The bill is bad for science and bad for America. If passed it would be an epic fail for America. Why? This
The Research Works Act Would Be An Epic Fail Read More »
It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper,
Why Lanza and I sold ACT stock Read More »
Today after years of following the company Advanced Cell Technology (ACT), I finally bought stock (ACTC) in it. Why? As a stem cell researcher myself working on human ES cells, iPS cells, and many other types of stem cells, I have been following ACT for years, but have never pulled the trigger to buy their stock….until
Why I finally bought stock in Advanced Cell Technology Read More »
Are street smarts important in science? Some of the smartest people I have ever met in my life were scientists. But some of these same people made the dumbest mistakes I have ever seen in my life. Why? Their raw brainpower and knowledge of science is amazing, but they seemed to lack common sense and
Science street smarts: how to succeed in science in the real world Read More »
It’s great to talk to Irv Weissman. It has been a week to think about mentors and I posted somewhat autobiographically on how to find and be a good mentor a few days ago. Also along these lines, I asked one of the great mentors of all time, Irv Weissman, about his early career and
Irv Weissman, his early career & mentors that made the difference Read More »
Who’s who in the field of iPS cells? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
How are things looking for the stem cell field for Spring 2011? Issue One. Getting to the clinic. At this point, Geron and ACT have their FDA-approved clinical trials underway using derivatives of human embryonic stem cells. As expected no news has leaked out on how things are going and it may well be Fall
Update on the stem cell field: Spring 2011 Read More »
Great ideas are the foundation of science, but funding makes great ideas become realities and a monopoly on funding hurts science. UPDATE: NIH data backs up our conclusions: overfunding wastes precious resources–give the money to smaller labs. Arguably the key driver of the exciting progress in stem cell research is funding. With the stakes so
Stem cell monopoly: do not pass go, do not collect $200,000 Read More »